Geode Capital Management LLC Boosts Stake in Twist Bioscience Co. (NASDAQ:TWST)

Geode Capital Management LLC boosted its position in shares of Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 0.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,374,667 shares of the company's stock after acquiring an additional 6,908 shares during the quarter. Geode Capital Management LLC owned 2.30% of Twist Bioscience worth $63,895,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the company. Wilmington Savings Fund Society FSB purchased a new stake in Twist Bioscience during the third quarter valued at approximately $34,000. Van ECK Associates Corp lifted its position in shares of Twist Bioscience by 56.4% during the 4th quarter. Van ECK Associates Corp now owns 740 shares of the company's stock valued at $34,000 after buying an additional 267 shares in the last quarter. US Bancorp DE grew its stake in shares of Twist Bioscience by 72.0% during the 4th quarter. US Bancorp DE now owns 1,436 shares of the company's stock valued at $67,000 after acquiring an additional 601 shares during the period. Beaird Harris Wealth Management LLC bought a new stake in shares of Twist Bioscience during the 3rd quarter valued at $95,000. Finally, KBC Group NV lifted its stake in Twist Bioscience by 71.4% in the 4th quarter. KBC Group NV now owns 2,942 shares of the company's stock worth $137,000 after purchasing an additional 1,226 shares in the last quarter.

Twist Bioscience Trading Down 4.3 %

Shares of NASDAQ TWST traded down $1.65 during mid-day trading on Friday, reaching $36.80. 747,299 shares of the company's stock were exchanged, compared to its average volume of 982,903. Twist Bioscience Co. has a 52-week low of $27.41 and a 52-week high of $60.90. The company's 50-day moving average is $40.75 and its 200-day moving average is $44.47. The firm has a market capitalization of $2.20 billion, a price-to-earnings ratio of -10.89 and a beta of 2.34. The company has a debt-to-equity ratio of 0.03, a quick ratio of 4.62 and a current ratio of 4.96.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last announced its quarterly earnings data on Monday, February 3rd. The company reported ($0.53) EPS for the quarter, topping analysts' consensus estimates of ($0.62) by $0.09. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The business had revenue of $88.70 million during the quarter, compared to the consensus estimate of $86.96 million. During the same period in the previous year, the company posted ($0.75) earnings per share. The business's revenue for the quarter was up 24.1% on a year-over-year basis. Analysts expect that Twist Bioscience Co. will post -2.12 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Emily M. Leproust sold 5,200 shares of Twist Bioscience stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $49.35, for a total value of $256,620.00. Following the transaction, the chief executive officer now directly owns 667,318 shares in the company, valued at $32,932,143.30. This trade represents a 0.77 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, COO Patrick John Finn sold 2,422 shares of the business's stock in a transaction dated Thursday, January 23rd. The stock was sold at an average price of $50.17, for a total transaction of $121,511.74. Following the transaction, the chief operating officer now owns 272,044 shares in the company, valued at approximately $13,648,447.48. This trade represents a 0.88 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 22,796 shares of company stock valued at $1,077,383. Insiders own 3.01% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the company. Guggenheim set a $50.00 price objective on Twist Bioscience in a research report on Friday, March 28th. JPMorgan Chase & Co. increased their target price on Twist Bioscience from $35.00 to $40.00 and gave the stock an "underweight" rating in a research note on Tuesday, February 4th. Robert W. Baird lifted their price objective on shares of Twist Bioscience from $48.00 to $54.00 and gave the company an "outperform" rating in a report on Tuesday, February 4th. Barclays lowered their price target on shares of Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating on the stock in a report on Thursday, April 10th. Finally, Scotiabank reiterated an "outperform" rating on shares of Twist Bioscience in a report on Tuesday, February 4th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $52.80.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.